SNWVHIGH SIGNALRISK10-K

SNWV disclosed material accounting errors requiring restatement of prior period financial statements, which should no longer be relied upon.

The company admitted to material misstatements in accounting for sales tax transactions that understated accrued expenses and resulted in recognition of previously unrecorded taxes, interest, and penalties. This represents a significant internal controls failure and undermines confidence in financial reporting quality, forcing investors to disregard all previously issued financial information.

Comparing 2026-03-26 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

Despite strong operational performance with revenue growing 44% to $44.1M and net income surging 187% to $11.8M, the accounting restatement casts doubt on these results' reliability. The company showed improved liquidity with operating cash flow jumping 596% to $3.9M and stockholders' equity turning positive from -$7.6M to $1.6M, while significantly reducing interest expense by 59%, but investors must view all metrics with heightened scrutiny given the material accounting errors disclosed.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+595.9%
$557K→$3.9M

Operating cash flow surged 595.9% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
+296.3%
$490K→$1.9M

Capital expenditure jumped 296.3% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
+186.7%
$4.1M→$11.8M

Net income grew 186.7% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+121.3%
-$7.6M→$1.6M

Equity base grew 121.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
+101%
$673K→$1.4M

R&D investment increased 101% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
+68.1%
$2.9M→$4.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
+62.9%
$3.3M→$5.4M

Receivables surged 62.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Interest Expense
P&L
-59.2%
$4.5M→$1.8M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+43.7%
$30.7M→$44.1M

Strong top-line growth of 43.7% — accelerating demand or successful expansion into new markets.

Inventory
Balance Sheet
+43%
$4.1M→$5.9M

Inventory surged 43% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-20
ADDED
As of March 24, 2026 , there were issued and outstanding 8,594,209 shares of the registrant s common stock.
Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
During the preparation of this Annual Report on Form 10-K, the Company determined that it had not appropriately accounted for certain transactions under US GAAP.
For the years ended December 31, 2024 and 2025, presented, the transactions related to sales tax, which led to an understatement of accrued expenses and a corresponding, non-recurring increase in expense due to the recognition of previously unrecorded taxes, associated interest, and penalties.
In accordance with Staff Accounting Bulletin ( SAB ) 99, Materiality , and SAB 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements , the Company evaluated the materiality of the errors from qualitative and quantitative perspectives, individually and in the aggregate, and concluded that the errors in aggregate were material to the consolidated financial statements for the affected periods.
+7 more — sign up free →
REMOVED
As of March 18, 2025 , there were issued and outstanding 8,548,473 shares of the registrant s common stock.
Food and Drug Administration ("FDA") approval of new products and new uses of our current products; financial markets; the competitive environment; supplier and customer disputes; and our plans to remediate our material weaknesses in our disclosure controls and procedures and our internal control over financial reporting.
The Company s patented and FDA cleared products include the UltraMIST system (UM) and the PACE family of products, both of which are used to treat a variety of acute and chronic wounds.
These products are backed by an intellectual property ( IP ) portfolio of over 165 patents.
In the year ended December 31, 2024 , we had total revenues of $32.6 million , a 60% increase from revenues of $20.4 million in the year ended December 31, 2023 .
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →